PDF 239kWORD 47k

pursuant to Rule 133 of the Rules of Procedure

on the development of an ‘artificial pancreas’ for people with diabetes type 1

Mireille D’Ornano

Motion for a European Parliament resolution on the development of an ‘artificial pancreas’ for people with diabetes type 1   

The European Parliament,

–  having regard to Article 168 of the Treaty on the Functioning of the European Union,

–  having regard to Rule 133 of its Rules of Procedure,

A.  whereas 33 million people in the European Union of 27 Member States suffer from diabetes (2010), this figure is expected to rise to 38 million by 2030 and around 6% are suffering from diabetes type 1; 

B.  whereas the US Food and Drug Administration on 28 September 2016 approved the MiniMed 670G closed loop system, commonly referred to as an ‘artificial pancreas’, which consists of a subcutaneous sensor that measures a patient’s blood glucose and a pump that automatically delivers insulin as required;

C.  whereas research into developing similar devices is also under way in some Member States, including in France at the Study and Research Centre for Intensified Diabetes Treatment, and whereas it is envisaged that an appliance could be placed on the market in 2017;

1.  Urges the Commission to support research aimed at the development and marketing of an ‘artificial pancreas’ and to make whatever efforts are necessary to speed up the authorisation procedures for placing such devices on the market.

Legal notice - Privacy policy